【藥品庫存】 藥品安全警訊 (藥品回收)食藥署今日 (2/13) 公告得時高凍晶注射劑400毫克，因為殘留類固醇，回收部分批號，本院使用之同成分藥品，產地、製造廠皆不同，不需回收。更新日期：2023/2/13。

Gram-positive infections
Surgical (orthopedic) prophylaxis

Antibiotic, Miscellaneous

Absorption
Tmax: (IM)2 hrs; (IV) end of infusion
Bioavailability: (IM)90%
Distribution
Protein binding, albumin: 87.6% to 90.8%
Vd: 0.7 to 1.4 L/kg
Excretion
Fecal: 2.7% unchanged (IV); 45% unchanged (oral)
Renal: 80% unchanged
Dialyzable: No
Elimination Half Life
Adults: 100 to 170 hours; Neonates: 40 hours; Pediatric (age 8 years): 58 hours

Hypersensitivity to teicoplanin or any component of the product

Fetal risk cannot be ruled out.

Infant risk cannot be ruled out

Common
Dermatologic: Erythema, Pruritus, Rash (1% to less than 10%)
Other: Fever (1% to less than 10%)
Serious
Dermatologic: Stevens-Johnson syndrome, Toxic epidermal necrolysis
Hematologic: Thrombocytopenia (0.1% to less than 1%)
Immunologic: Anaphylaxis (0.1% to less than 1%), Hypersensitivity reaction
Otic: Toxic deafness (0.1% to less than 1%)
Renal: Renal failure

Gram-positive infections:
Initial 6-12 mg/kg Q12H for 3 to 5 doses; Maintenance 6-12 mg/kg QD to achieve targeted trough concentration
Surgical (orthopedic) prophylaxis:
400 mg (or 6 mg/kg) given once at induction of anesthesia

Neonates and Infants <2 months:
(IV) Initial 16 mg/kg loading dose on day 1, followed by 8 mg/kg once daily starting on day 2
Infants ≥2 months and Children ≤12 years:
(IV) Initial 10 mg/kg every 12 hours for 3 doses, followed by 6 to 10 mg/kg once daily

1. Mild impairment (CrCl 40-60 mL/min): half dose or initial dose given QOD
2. Severe impairment (CrCl <40 mL/min): 1/3 dose